Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14-ii17.
[2]
McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42(6):778-783.
[3]
Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiographic study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42(12):1460-1468.
[4]
Coaccioli S, Di Carlo S, Fatuzzo F, et al. Arthritis mutilans: a review. Clin Ter. 2020;171(4):e303-e309.
[5]
Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity. Ann Rheum Dis. 2005;64(2):188-190.
[6]
Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol. 1994;33(2):133-138.
[7]
Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis. 1973;32(3):181-201.
Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4-12.
[10]
Perrotta FM, Marchesano A, Massara G, et al. Arthritis mutilans in psoriatic arthritis: a case series. Reumatismo. 2016;68(2):99-103.